- On October 22, the 2nd China International Bio & Chemical Pharmaceutical Technology Service Expo (2020) 2ndcmc Expo China was held in Suzhou (2020), with the theme of “improving R & D efficiency and reducing manufacturing costs”
- Become shengnuo biotechnology one-stop cdmo service platform and appear in the second CMC Expo of China
- The Expo strives to solve many problems in the current biomedical environment through a number of measures such as seeking the best raw material drugs, preparations, technology development, consulting and commissioned processing services (CRO, CMO & cdmo partner) for participating enterprises.
- Shengnuo Biotechnology Pharmaceutical Co., Ltd., established in 2001, is a national high-tech certification enterprise, with more than 450 employees, including more than 150 people engaged in peptide drug cdmo.
- CDMO is an in-depth penetration of the entire industrial chain from preclinical research, clinical trials to product production.
On October 22, the 2nd China International Bio & Chemical Pharmaceutical Technology Service Expo (2020) 2ndcmc Expo China was held in Suzhou (2020), with the theme of “improving R & D efficiency and reducing manufacturing costs”
the Expo invited more than 100 pharmaceutical administration leaders, industry celebrities, and more than 500 entrepreneurs to share and exchange more than 50 hot topics and technology hotspots such as China’s biomedical innovation cooperation and trend,
pharmaceutical enterprises after centralized procurement and expansion Biotechnology Pharmaceutical Co., Ltd. (hereinafter referred to as Shengnuo Biotechnology) was invited to participate in the meeting and presented the one-stop cdmo service platform project for CMC research of peptide drugs.
Become shengnuo biotechnology one-stop cdmo service platform and appear in the second CMC Expo of China
In the novel coronavirus, the global pattern of bio pharmaceutical industry has undergone tremendous changes in recent two years. Under the development of novel coronavirus vaccines and related test reagents worldwide,
the world’s major countries and regions have to face the dependence of external pharmaceutical raw materials. The theme of the Expo is to “improve R & D efficiency and reduce manufacturing costs”, which is the consideration and decision of the current situation.
The Expo strives to solve many problems in the current biomedical environment through a number of measures such as seeking the best raw material drugs, preparations, technology development, consulting and commissioned processing services (CRO, CMO & cdmo partner) for participating enterprises.
During the Expo, shengnuo biotechnology brought a one-stop cdmo service platform for innovative polypeptide drugs.
With years of practice and accumulation of polypeptide related industry technology, shengnuo biotechnology showed the professionalism of its whole process team in API, preparation, quality and registration.
The workshop and system of GMP (preparation) in line with international standard GMP (API) and domestic GMP (preparation), complete production lines of various dosage forms, independent small-scale and pilot production, production quality and registration team, etc., also highlight the characteristics and advantages of shengnuo biotechnology one-stop peptide cdmo service.
Shengnuo Biotechnology Pharmaceutical Co., Ltd., established in 2001, is a national high-tech certification enterprise, with more than 450 employees, including more than 150 people engaged in peptide drug cdmo.
The company has established “Sichuan peptide drug engineering technology research center” and “shengnuo biotechnology Joint Laboratory of Sichuan University”, with mature peptide industrialization ability.
The cdmo service of polypeptide drugs has a complete domestic peptide drug research platform, including independent raw material pilot production workshop, independent raw material pilot production workshop and corresponding independent research team.
CDMO is an in-depth penetration of the entire industrial chain from preclinical research, clinical trials to product production.
It provides innovative process research and development and production services for enterprises, and replaces the pure output of production capacity with high value-added technology output.
It is a new cooperation mode in the biomedical industry. Under the severe situation of the global biomedical industry, the development and innovation of cdmo are also full of challenges and opportunities.
We also hope that shengnuo biotechnology one-stop cdmo service platform will strive to be first-class in the future development and make more contributions to the field of Chinese biomedicine.
For sale, buy peptides, purchase peptides, and buy peptides online, you can find the Chinese peptide company:
Shengnuo Biotechnology is a high-tech China polypeptide manufacturers,who has over 19 years experience for the biotechnology .Our Products involve peptide raw materials,polypeptide drug.
Our 0 defect has passed the FDA certification, and has become the first-class professional polypeptide drug and product development and large-scale production and export industry in China .
Our service scope：peptide synthesis、peptide hormones、peptide medicine、beauty peptide、peptide medicine product、peptide technology transfer、peptide technology service、peptide large-scale production、export of peptide
Thymopentin for Injection、 Thymalfasin for Injection 、 Bivalirudin 、Bulk Drug、 Liraglutide ……